Navigation Links
Novelos Therapeutics Prices $5.5 Million Public Offering
Date:2/13/2013

MADISON, Wis., Feb. 13, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 11,000,000 units at $0.50 per unit for gross proceeds of $5,500,000.  Each unit consists of one share of our common stock, a Class A Warrant with a one-year term to purchase one-half of a share of our common stock at an exercise price of $0.50 per share and a Class B Warrant with a five-year term to purchase one share of our common stock at an exercise price of $0.50 per share.  Novelos expects to close the transaction, subject to customary conditions, on or about February 19, 2013.

Burrill Securities LLC is acting as a placement agent in a co-lead capacity for the offering.  Dawson James Securities, Inc. is acting as a sub-agent in a co-lead capacity.

The Benchmark Company, LLC is acting as a sub-agent.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer or sale of these securities in any jurisdiction or to any person in any particular jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering will be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from Burrill Securities LLC, Prospectus Department, One Embarcadero Center, Suite 2700, San Francisco, CA 94111, 415-591-5400 or email: ksheinerman@b-c.com.  Before any investment, an investor should read the prospectus supplement and the accompanying prospectus, including the information incorporated by reference therein, for more complete information about Novelos and this offering.

INVESTOR CONTACTS
J. Patrick Genn , Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fields , Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com, @LHA_IR_PR

This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  Such statements are valid only as of today, and we disclaim any obligation to update this information.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.


'/>"/>
SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
2. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
3. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
4. Novelos Therapeutics Closes $2 Million Private Placement
5. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
6. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
7. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
8. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
9. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
10. Novelos Therapeutics Prices $5.4 Million Public Offering
11. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... WARSAW, Ind. , Sept. 7, 2017  Zimmer ... leader in musculoskeletal healthcare, today announced that it will ... Annual Global Healthcare Conference at the Grand Hyatt hotel ... September 11, 2017 at 11:40 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:9/6/2017)... -- NeuroRx, a clinical stage biopharma company developing the first ... been granted Fast Track status by the US Food and ... followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly ... therapy targeting patients who are admitted to Emergency Departments with ... ...
(Date:9/5/2017)...  Just 18 months after its February 2016 launch, ... the appointment of three new senior people to its ... Jones-Phillips and James Wright bring decades ... Tammy Wynne joins as Director, ... She has over ten years, experience in global market ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... International Water Advocate Sharon Kleyne ... Hour Power of Water, Global Climate Change and Your Health on VoiceAmerica sponsored ... a once-every-four-years series of events to a personal, daily Health Olympics. “Wouldn’t it ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... and efficiency. The principle of First-Defect-Stop for laboratory weighing is designed ... have the chance to have negative consequences on downstream processes. , If a ...
(Date:9/25/2017)... ... September 25, 2017 , ... Bobbie Horowitz was hardly ... and multiple health issues. As a cabaret and theater producer, Horowitz would manage to ... source of transportation in New York City, so she had to take a cab ...
(Date:9/25/2017)... ... , ... METTLER TOLEDO is pleased to host the 3rd Annual Metrology ... symposium will feature speakers from North American National Measurement Institutes (NMI) with a purpose ... planning for the future of the modern lab. , The event is not just ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... research, today announces that 30 of its domain experts will present on ... at upcoming industry conferences and webinars. Drawing on broad and deep industry ...
Breaking Medicine News(10 mins):